Bolt Biotherapeutics (BOLT) Appoints Laura Berner to Board of Directors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Bolt Biotherapeutics Appoints Laura Berner to Board of Directors
December 14, 2022 4:43 PM ESTREDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022.
Laura is an accomplished biopharmaceutical executive with impressive corporate leadership, operations, and business development experience, said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics. As we continue to advance our immuno-oncology pipeline programs in the clinic, Laura brings important strategic perspective from leading and executing more than 50 transactions including research collaborations and... More
